Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.85 |
| ▸ | F2 | P00734 | 4/20 | 0.85 |
| ▸ | F7 | P08709 | 3/20 | 0.85 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.72 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.72 |
| ▸ | PLG | P00747 | 1/20 | 0.72 |
| ▸ | PLAU | P00749 | 1/20 | 0.72 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.72 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.72 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.70 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.70 |
| ▸ | KLK1 | P06870 | 1/20 | 0.61 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30386514 | 0.99 | F10 (0.82) | F10F2F7TPSAB1PRSS1 | |
| Hydrochloric Acid SCHEMBL28579078 | 0.99 | F10 (0.82) | F10F2F7TPSAB1PRSS1 | |
| SCHEMBL65730 | 0.93 | F10 (0.77) | F10F2F7TPSAB1PRSS1 | |
| SCHEMBL7479169 | 0.92 | F10 (0.71) | F10F2F7TPSAB1PRSS1 | |
| SCHEMBL29354281 | 0.92 | F10 (1.00) | F10F2F7TPSAB1PRSS1 | |
| SCHEMBL4322200 | 0.91 | TPSAB1 (0.78) | F10F2F7TPSAB1PRSS1 | |
| SCHEMBL7406681 | 0.86 | F10 (0.68) | F10F2F7TPSAB1PRSS1 | |
| SCHEMBL7406105 | 0.86 | F10 (0.68) | F10F2F7TPSAB1PRSS1 | |
| SCHEMBL7406230 | 0.86 | F10 (0.64) | F10F2F7TPSAB1PRSS1 | |
| SCHEMBL7406430 | 0.85 | F10 (0.76) | F10F2F7TPSAB1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210292436-A1 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | OMEROS CORPORATION | 2021-09-23 | — | — | US | disclosed |
| WO-2021178902-A1 | METHODS OF INHIBITING MASP-2 FOR THE TREATMENT AND/OR PREVENTION OF CORONAVIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME | OMEROS CORPORATION (US) | 2021-09-10 | — | — | WO | disclosed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20100324058-A1 | THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | OBSCHESTVO S ORGANICHENNOI OTVETSTTVENNOCTIYOU "BIONIKA" (RU) | 2010-12-23 | — | — | US | disclosed |
| US-20100324058-A1 | THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | OBSCHESTVO S ORGANICHENNOI OTVETSTTVENNOCTIYOU "BIONIKA" (RU) | 2010-12-23 | — | — | US | disclosed |
| WO-2009002228-A2 | NEW THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | OBSCHESTVO S OGRANICHENNOI OTVETSTTVENNOCTIYU 'BIONIKA' (RU) | 2008-12-31 | — | — | WO | disclosed |
| EP-0943008-B1 | METAL MEDIATED SERINE PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6355460-B1 | DETECTING ENZYME INHIBITORS; INCUBATE ENZYME WITH MODULATOR, MONITOR SAMPLE FOR REDUCTION IN ENZYME ACTIVITY, REDUCTION IN ENZYME ACTIVITY INDICATES MODULATOR | AXYS PHARMACEUTICALS, INC. | 2002-03-12 | — | — | US | disclosed |
| US-6255091-B1 | ASSAYING FOR ENHANCED INHIBITION OF SERINE PROTEASE IN A MEDIUM THAT IS DEVOID OF DISSACIATED DIVALENT METAL CATIONS | AXYS PHARMACEUTICALS, INC. | 2001-07-03 | — | — | US | disclosed |
| EP-0943008-A1 | METAL MEDIATED SERINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022619-A1 | METAL MEDIATED SERINE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | F10 4171/4885F2 4188/4885F7 4785/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | F10 4171/4885F2 4188/4885F7 4785/4885 |
| US-20210292436-A1 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | MASP2, ACE2, MAS1 | F10 299/4885F2 36/4885F7 930/4885 |
| US-20100324058-A1 | THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | F2, PLAT, SERPINC1 | F10 23/4885F2 1/4885F7 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.